tbuckley/cabot-search huggingface dataset:
Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma
Authors: Paolo Strati, Sairah Ahmed, Fateeha Furqan, Luis E. Fayad, Hun J. Lee, Swaminathan P. Iyer, Ranjit Nair, Loretta J. Nastoupil, Simrit Parmar, Maria A. Rodriguez, Felipe Samaniego, Raphael E. Steiner, Michael Wang, Chelsea C. Pinnix, Sandra B. Horowitz, Lei Feng, Ryan Sun, Catherine M. Claussen, Misha C. Hawkins, Nicole A. Johnson, Prachee Singh, Haleigh Mistry, Swapna Johncy, Sherry Adkins, Partow Kebriaei, Elizabeth J. Shpall, Michael R. Green, Christopher R. Flowers, Jason Westin, Sattva S. Neelapu
Journal: Blood (2021)
Combined hepatocellular-cholangiocarcinoma: An update
Authors: Aurélie Beaufrère, Julien Calderaro, Valérie Paradis
Journal: Journal of Hepatology (2021)

Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a tumour that exhibits both hepatocytic and biliary differentiation. Classical risk factors for hepatocellular carcinoma (HCC) seem to also predispose patients to the development of cHCC-CCA. The pathological definition of cHCC-CCA has significantly evolved over time. The last 2019 WHO classification highlighted that the diagnosis of cHCC-CCA should be primarily based on morphology using routine stainings, with additional immunostaining used to refine the identification of subtypes. Among them, "intermediate cell carcinoma" is recognised as a specific subtype, while "cholangiolocellular carcinoma" is now considered a subtype of iCCA. Increasing molecular evidence supports the clonal nature of cHCC-CCA and parallels its biphenotypic histological appearance, with genetic alterations that are classically observed in HCC and/or iCCA. That said, the morphological diagnosis of cHCC-CCA is still challenging for radiologists and pathologists, especially on biopsy specimens. Identification of cHCC-CCA's cell of origin remains an area of active research. Its prognosis is generally worse than that of HCC, and similar to that of iCCA. Resection with lymph node dissection is unfortunately the only curative option for patients with cHCC-CCA. Thus, there remains an urgent need to develop specific therapeutic strategies for this unique clinical entity.
Covid-19: South Africa pauses use of Oxford vaccine after study casts doubt on efficacy against variant
Authors: Elisabeth Mahase
Journal: BMJ (2021)

Covid-19: South Africa pauses use of Oxford vaccine after study casts doubt on efficacy against variant Elisabeth MahaseRollout of the Oxford-AstraZeneca covid-19 vaccine in South Africa has been paused after a study in 2000 healthy and young volunteers reported that it did not protect against mild and moderate disease caused by the new variant (501Y.V2) that emerged there.
Abstract 14155: Pressure Overload is Associated with Low Levels of Troponin I and Myosin Binding Protein C Phosphorylation in the Hearts of Patients with Aortic Stenosis
Authors: Steven B Marston, O'Neal Copeland, Andrew Messer, Corrado Poggesi, Sanjay Prasad, Andrew Jabbour
Journal: Circulation (2012)

In previous studies of septal heart muscle from HCM patients with hypertrophic obstructive cardiomyopathy (HOCM, LVOT gradient 50-100mmHg) we found that the level of phosphorylation of troponin I (...
Safety of a 3-Step "Catch-Up Protocol” in Re-establishing Maintenance Dose Subcutaneous Immunotherapy (SCIT) Post Covid-19 Lockdown During Allergy Season.
Authors: Ijaz Ogeer, Wardha. Wardha, Vaidehi Bhatt, Vince Wu, Saajida Hosein, Tyler Seto, Tenzin Gyaltsen
Journal: Journal of Allergy and Clinical Immunology (2021)

Guidelines for SCIT dose catch up schedules are limited. Statement 51 of the AAAAI Practice Parameter recommends dose reduction based on interval interruptions, without firm dose recommendations. In light of the COVID-19 lockdown a 3 Step Catch Up Protocol was implemented in a community clinic to achieve patients' maintenance SCIT dosing in a timely and safe manner. A retrospective study followed patients offered a 3-Step Catch Up Protocol (CUP) to maintenance dosing for their inhalant allergen SCIT. CUP was calculated with initial dose of 50% of maintenance, followed by 80% and 100% respectively on weekly basis. Afterwards, from week 4 onward patients resumed maintenance schedule. All adverse events were recorded. Pulmonary function evaluation was deferred due to Covid restrictions. Individuals on Vespid immunotherapy and patients on routine SCIT build up phases were excluded. Fifty-four patients were evaluated with a mean age of 37 years (CI 32.03 to 41.97. Two patients discontinued SCIT for concerns of Covid exposure in clinic. SCIT single allergen represented 12% of patients and 88% received multiallergen SCIT. Due to lockdown, the mean absence time from last SCIT was 11 wks (CI 10.74 to 11.78). Large local adverse reactions were reported in 2/52 patients (3.8%) and systemic in 2/52 (3.8%) patients, 1 severe requiring epinephrine. The 2 with systemic reactions also had prior systemic reactions on standard build-up of SCIT. A 3-step Catch Up Protocol in achieving maintenance SCIT dosing during allergy season was safe and did not yield increase anaphylactic reactions compared to standard updosing.
Fibrous Systems as Potential Solutions for Tendon and Ligament Repair, Healing, and Regeneration
Authors: Chiara Rinoldi, Ewa Kijeńska‐Gawrońska, Ali Khademhosseini, Ali Tamayol, Wojciech Swieszkowski
Journal: Advanced Healthcare Materials (2021)

Tendon and ligament injuries caused by trauma and degenerative diseases are frequent and affect diverse groups of the population. Such injuries reduce musculoskeletal performance, limit joint mobility, and lower people's comfort. Currently, various treatment strategies and surgical procedures are used to heal, repair, and restore the native tissue function. However, these strategies are inadequate and, in some cases, fail to re-establish the lost functionality. Tissue engineering and regenerative medicine approaches aim to overcome these disadvantages by stimulating the regeneration and formation of neotissues. Design and fabrication of artificial scaffolds with tailored mechanical properties are crucial for restoring the mechanical function of tendons. In this review, the tendon and ligament structure, their physiology, and performance are presented. On the other hand, the requirements are focused for the development of an effective reconstruction device. The most common fiber-based scaffolding systems are also described for tendon and ligament tissue regeneration like strand fibers, woven, knitted, braided, and braid-twisted fibrous structures, as well as electrospun and wet-spun constructs, discussing critically the advantages and limitations of their utilization. Finally, the potential of multilayered systems as the most effective candidates for tendon and ligaments tissue engineering is pointed out.
Microneedle Arrays: Directly Compressed Tablets: A Novel Drug‐Containing Reservoir Combined with Hydrogel‐Forming Microneedle Arrays for Transdermal Drug Delivery (Adv. Healthcare Mater. 3/2021)
Authors: Emma McAlister, Bridie Dutton, Lalitkumar K. Vora, Li Zhao, Anastasia Ripolin, Dk Siti Zawanah Binti Pg Hj Zahari, Helen L. Quinn, Ismaiel A. Tekko, Aaron J. Courtenay, Stephen A. Kelly, Aoife M. Rodgers, Lilach Steiner, Galit Levin, Etgar Levy‐Nissenbaum, Nava Shterman, Helen O. McCarthy, Ryan F. Donnelly
Journal: Advanced Healthcare Materials (2021)

A microneedle (MN) patch consists of a hydrogel-forming MN array and a drug-containing reservoir. Upon insertion into the skin, these MN patches rapidly imbibe skin interstitial fluid and swell. In article number 2001256 by Ryan F. Donnelly and co-workers, continuous, unblockable, hydrogel conduits are formed through which drugs can reach the dermal microcirculation. This cover design represents the work conducted with these novel MN patches.
Patients with Central Nervous System Lymphoma Undergoing Thiotepa, Busulfan, and Cyclophosphamide-Conditioned Autologous Stem Cell Transplantation Are at a Higher Risk for DNA Virus Infections Than Patients with Systemic Non-Hodgkin Lymphoma Receiving Traditional Conditioning
Authors: Michael Scordo, Sejal M. Morjaria, Ankush Bhatia, Eric R. Littmann, Molly Maloy, Lisa DeAngelis, Sergio A. Giralt, Ying Taur, Craig S. Sauter
Journal: Blood (2017)
Correspondence on ‘Bowman’s capsule rupture on renal biopsy improves the outcome prediction of ANCA-associated glomerulonephritis classifications’
Authors: Samy Hakroush, Björn Tampe
Journal: Annals of the Rheumatic Diseases (2021)

Bowman’s capsule rupture was first reported more than 30 years ago and only few case reports described its presence in diseased kidneys to date.1 We read with great interest the recent article by L'Imperio et al reporting that presence of Bowman’s capsule rupture was significantly associated with renal outcome in patients with antineutrophil cytoplasm antibodies (ANCA)-associated glomerulonephritis (GN).2 Furthermore, a better performance of the established histopathological subtyping proposed by Berden et al and Brix et al was observed after the implementation of Bowman’s capsule rupture to the classification systems.2–4 While these findings are of great interest and require further validation, the overall prevalence of Bowman’s capsule rupture in ANCA GN remains elusive. Here, we describe the frequency of Bowman’s capsule rupture within 44 renal biopsies with confirmed ANCA GN.

In our single-centre cohort, we observed the presence of extensive Bowman’s capsule rupture …
USPSTF Recommendations for Screening for Carotid Stenosis to Prevent Stroke—The Need for More Data
Authors: Rebecca Smith-Bindman, Kirsten Bibbins-Domingo
Journal: JAMA Network Open (2021)

US Preventive Services Task Force; Alex H. Krist, MD, MPH; Karina W. Davidson, PhD, MASc; Carol M. Mangione, MD, MSPH; Michael J. Barry, MD; Michael Cabana, MD, MA, MPH; Aaron B. Caughey, MD, PhD; Katrina Donahue, MD, MPH; Chyke A. Doubeni, MD, MPH; John W. Epling Jr, MD, MSEd; Martha Kubik, PhD, RN; Gbenga Ogedegbe, MD, MPH; Lori Pbert, PhD; Michael Silverstein, MD, MPH; Melissa A. Simon, MD, MPH; Chien-Wen Tseng, MD, MPH, MSEE; John B. Wong, MD
Abstract 12788: Induced Pluripotent Stem Cells and Their Derivatives From Patients of Kearns-Sayre Syndrome Help Establish a Stable In Vitro Model
Authors: Glen Lester Sequiera, Meenal Moudgil, Niketa Sareen, Ejlal Abu El Rub, Cheryl Rockman-Greenberg, Sanjiv Dhingra
Journal: Circulation (2018)

Background: Inborn mitochondrial disorders have been regularly associated with cardiomyopathies. Mitochondrial diseases are caused by dysfunction in mitochondrial respiratory chain complexes, leadi...
The 9p21 Locus and Coronary Heart Disease: Initiator, Promoter, or Precipitator?⁎⁎Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.
Authors: Jeffrey L. Anderson, Benjamin D. Horne
Journal: Journal of the American College of Cardiology (2010)
Interpretation of the Seattle Angina Questionnaire as an Outcome Measure in Clinical Trials and Clinical Care
Authors: Merrill Thomas, Philip G. Jones, Suzanne V. Arnold, John A. Spertus
Journal: JAMA Cardiology (2021)

Patient-reported outcomes are increasingly used as end points in clinical trials, assessments in clinical care, and tools for population health, with an increasing role in quality assessment. For patients with coronary artery disease, the Seattle Angina Questionnaire (SAQ) has emerged as the most commonly used measure of disease-specific health status to quantify patients' symptoms of angina and the extent to which their angina affects their functioning and quality of life. This review explains how to interpret the SAQ and describes the construction and face validity of the SAQ, focusing on aligning scores and changes in scores with clinical constructs.The SAQ asks questions similar to those an experienced clinician would ask of a patient with stable ischemic heart disease. Therefore, SAQ scores can be aligned with clinical constructs (eg, scores on the SAQ angina frequency scale of 0-30 points indicate daily angina, 31-60 points indicate weekly angina, 61-99 points indicate monthly angina, and 100 points indicate no angina), and changes in scores can be described by aligning them with changes in question responses. After clinical thresholds are defined, it is important for clinical trials to not simply report mean differences between treatment arms but to also report the distributions of patients who have had clinically important benefits so that a number needed to treat can be generated.The widespread use of the SAQ is a consequence of its well-established validity, reproducibility, prognostic importance, and sensitivity to clinical change. Nevertheless, interpreting the SAQ can be challenging because of lack of familiarity with the clinical importance of its domains, either cross-sectionally or longitudinally. This review provides an overview of the interpretability of the SAQ as a foundation for its use as an end point in clinical trials, a tool to support more patient-centered care, and a means of facilitating population health strategies to provide a better foundation for the integration of patient experiences with clinical care.
Circulating Platelet Vs Megakaryocyte-Derived Microparticles Identify Myelofibrosis Patients with JAK2V617F Mutation, High Disease Burden and Ruxolitinib Response
Authors: Dorian Forte, Martina Barone, Francesca Ricci, Daria Sollazzo, Marco Romano, Emanuela Ottaviani, Giuseppe Auteri, Nicola Vianelli, Giovanni Martinelli, Michele Cavo, Pierluigi Tazzari, Francesca Palandri, Lucia Catani
Journal: Blood (2017)
Ketamine and the Future of Rapid-Acting Antidepressants
Authors: Lace M. Riggs, Todd D. Gould
Journal: Annual Review of Clinical Psychology (2021)

The therapeutic onset of traditional antidepressants is delayed by several weeks and many depressed patients fail to respond to treatment altogether. In contrast, subanesthetic ketamine can rapidly alleviate symptoms of depression within hours of a single administration, even in patients who are considered treatment-resistant. Ketamine is thought to exert these effects by restoring the integrity of neural circuits that are compromised in depression. This hypothesis stems in part from preclinical observations that ketamine can strengthen synaptic connections by increasing glutamate-mediated neurotransmission and promoting rapid neurotrophic factor release. An improved understanding of how ketamine, and other novel rapid-acting antidepressants, give rise to these processes will help foster future therapeutic innovation. Here, we review the history of antidepressant treatment advances that preceded the ketamine discovery, critically examine mechanistic hypotheses for how ketamine may exert its antidepressant effects, and discuss the impact this knowledge has had on ongoing drug discovery efforts.
Abstract 13884: A Patient With Barth Syndrome
Authors: Arjun Kanwal, Jason Kaplan, Raman Bharaj, Aditya Saini
Journal: Circulation (2019)

Introduction: Barth syndrome (BTHS), a rare condition with an incidence of 1 in 400,000, was first described in 1983 as an X-Linked recessive genetic disorder caused by mutations in the TAZ gene. W...
A novel immunochemotherapy based on targeting of cyclooxygenase and induction of immunogenic cell death
Authors: Haozhe Huang, Yixian Huang, Yuang Chen, Zhangyi Luo, Ziqian Zhang, Runzi Sun, Zhuoya Wan, Jingjing Sun, Binfeng Lu, Lin Zhang, Jing Hu, Song Li
Journal: Biomaterials (2021)
High Mobility Group Box 1 Release by Cholangiocytes Governs Biliary Atresia Pathogenesis and Correlates With Increases in Afflicted Infants
Authors: Sujit K. Mohanty, Bryan Donnelly, Haley Temple, Ana Ortiz‐Perez, Sarah Mowery, Inna Lobeck, Phylicia Dupree, Holly M. Poling, Monica McNeal, Reena Mourya, Todd Jenkins, Ruchi Bansal, Jorge Bezerra, Greg Tiao
Journal: Hepatology (2021)

Biliary atresia (BA) is a devastating cholangiopathy of infancy. Upon diagnosis, surgical reconstruction by Kasai hepatoportoenterostomy (HPE) restores biliary drainage in a subset of patients, but most patients develop fibrosis and progress to end-stage liver disease requiring liver transplantation for survival. In the murine model of BA, rhesus rotavirus (RRV) infection of newborn pups results in a cholangiopathy paralleling that of human BA. High-mobility group box 1 (HMGB1) is an important member of the danger-associated molecular patterns capable of mediating inflammation during infection-associated responses. In this study, we investigated the role of HMGB1 in BA pathogenesis.In cholangiocytes, RRV induced the expression and release of HMGB1 through the p38 mitogen-activated protein kinase signaling pathway, and inhibition of p38 blocked HMGB1 release. Treatment of cholangiocytes with ethyl pyruvate suppressed the release of HMGB1. Administration of glycyrrhizin in vivo decreased symptoms and increased survival in the murine model of BA. HMGB1 levels were measured in serum obtained from infants with BA enrolled in the PROBE and START studies conducted by the Childhood Liver Disease Research Network. High HMGB1 levels were found in a subset of patients at the time of HPE. These patients had higher bilirubin levels 3 months post-HPE and a lower survival of their native liver at 2 years.These results suggest that HMGB1 plays a role in virus induced BA pathogenesis and could be a target for therapeutic interventions in a subset of patients with BA and high HMGB1.
Evaluation of the Sleep Profile in Women with Severe Obesity
Authors: Gabriela Girade, Marcela de Oliveira Queiroz, Nayra Figueiredo, Karem Lays Soares Lopes, Roseli Neves de Melo, Paula Ribeiro Toscano de Brito, Giovana Tassinari Caixeta, Maria Aderuza Horst, Valéria de Souza Abreu, Barbara Paixao de Gois, Flavia Campos Co
Journal: Metabolism (2021)
Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors
Authors: James Spicer, Aurélien Marabelle, Jean-Francois Baurain, Nina Louise Jebsen, Dag Erik Jøssang, Ahmad Awada, Rebecca Kristeleit, Delphine Loirat, George Lazaridis, Christiane Jungels, Paal Brunsvig, Berit Nicolaisen, Andrew Saunders, Hamina Patel, Jérôme Galon, Fabienne Hermitte, Ketil André Camilio, Brynjar Mauseth, Vibeke Sundvold, Baldur Sveinbjørnsson, Øystein Rekdal
Journal: Clinical Cancer Research (2021)

LTX-315 is a first-in-class, 9-mer membranolytic peptide that has shown potent immunomodulatory properties in preclinical models. We conducted a phase I dose-escalating study of intratumoral LTX-315 administration in patients with advanced solid tumors.Thirty-nine patients were enrolled, receiving LTX-315 injections into accessible tumors. The primary objective was to assess the safety and tolerability of this approach, with antitumor and immunomodulatory activity as secondary objectives. Tumor biopsies were collected at baseline and posttreatment for analysis of immunologic parameters.The most common treatment-related grade 1-2 adverse events were vascular disorders including transient hypotension (18 patients, 46%), flushing (11 patients, 28%), and injection site reactions in 38% of patients. The most common grade 3 LTX-315-related toxicities were hypersensitivity or anaphylaxis (4 patients, 10%). Analysis of immune endpoints in serial biopsies indicated that LTX-315 induces necrosis and CD8+ T-cell infiltration into the tumor microenvironment. Sequencing of the T-cell receptor repertoire in peripheral blood identified significant expansion of T-cell clones after treatment, of which 49% were present in available tumor biopsies after treatment, suggesting that they were tumor associated. Substantial volume reduction (≥30%) of injected tumors occurred in 29% of the patients, and 86% (12/14 biopsies) had an increase in intralesional CD8+ T cells posttreatment. No partial responses by immune-related response criteria were seen, but evidence of abscopal effect was demonstrated following treatment with LTX-315.LTX-315 has an acceptable safety profile, is clinically active, induces changes in the tumor microenvironment and contributes to immune-mediated anticancer activity.
Web-based Infant Food Introduction (WIFI): Improving Access to Allergist-supervised Infant Food Introduction
Authors: Meriem Latrous, Rongbo Zhu, Samira Jeimy, Douglas Mack, Lianne Soller, Edmond Chan, Jennifer Protudjer, Mariam Hanna, Elissa Abrams, Victoria Cook, Scott Cameron, Stephanie Erdle, Tiffany Wong
Journal: Journal of Allergy and Clinical Immunology (2021)
Assessing Severity in Common variable immune deficiency (CVID) using the "Ameratunga Score- AS"
Authors: Rafaela Guimaraes, Luiza Schmid, Lígia Machado, Mariana Pimentel, Maria Cândida Rizzo, Carolina Aranda, Dirceu Sole
Journal: Journal of Allergy and Clinical Immunology (2021)
Optimal Time Point for 68Ga-PSMA-11 PET/CT Imaging in the Assessment of Suspected Metastatic Prostate Cancer in the Bladder of Postprostatectomy Patient
Authors: Guofan Xu, Yang Lu
Journal: Clinical Nuclear Medicine (2021)

Abstract A 77-year-old man with prostate cancer had prostatectomy and hormonal therapy and underwent pelvic MRI and 68 Ga-PSMA-11 PET/CT during clinical follow-up. A pelvic MRI scan showed suspected metastasis along the posterior wall of urinary bladder. The 68 Ga-PSMA-11 PET/CT was acquired in a dual-time point fashion, at 60 minutes and 110 minutes postinjection. At 60 minutes postinjection, the known bladder wall lesion showed lower than urine background uptake. On 110 minutes delayed images, the bladder wall lesion showed avid PSMA uptake, much higher than the urine background, increased PSMA uptake by the tumor over time, and improved contrast in the lesion.
Identification and modulation of the peripheral innate lymphoid cells type 2 in LTP-allergic patients treated with Pru p 3 Sublingual Immunotherapy.
Authors: Maria Francisca Palomares Jerez, Francisca Gomez, Gádor Bogas, María José Rodríguez, Rosa Muñoz-Cano, María José Torres, Cristobalina Mayorga
Journal: Journal of Allergy and Clinical Immunology (2021)
Hepatic Vasculopathy and Regenerative Responses of the Liver in Fatal Cases of COVID-19
Authors: Barbara Kaltschmidt, Antonia D.E. Fitzek, Julia Schaedler, Christine Förster, Christian Kaltschmidt, Torsten Hansen, Fabian Steinfurth, Beatrice A. Windmöller, Christian Pilger, Cihang Kong, Kashika Singh, Axel Nierhaus, Dominic Wichmann, Jan Sperhake, Klaus Püschel, Thomas Huser, Martin Krüger, Simon C. Robson, Ludwig Wilkens, Jan Schulte am Esch
Journal: Clinical Gastroenterology and Hepatology (2021)

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infects the nasopharynx and lungs and causes coronavirus disease-2019 (COVID-19). It may impact the heart, brain, kidney, and liver.
Erratum to: Non-nucleoside reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and hepatic steatosis [J Hepatol (2019); 70 (5): 930–940]
Authors: Taesik Gwag, Zhaojie Meng, Yipeng Sui, Robert N. Helsley, Se-Hyung Park, Shuxia Wang, Richard N. Greenberg, Changcheng Zhou
Journal: Journal of Hepatology (2021)
SARS-CoV-2 vaccines and donor recruitment for FMT
Authors: Gianluca Ianiro, Benjamin H Mullish, Christian Lodberg Hvas, Jonathan P Segal, Ed J Kuijper, Samuel P Costello, Colleen R Kelly, Jessica R Allegretti, Monika Fischer, Tariq H Iqbal, Reetta Satokari, Dina Kao, Joffrey van Prehn, Siew C Ng, Stefano Bibbò, Simon Mark Dahl Baunwall, Mohammed N Quraishi, Harry Sokol, Faming Zhang, Josbert Keller, Luca Masucci, Gianluca Quaranta, Zain Kassam, Maurizio Sanguinetti, Herbert Tilg, Antonio Gasbarrini, Giovanni Cammarota
Journal: The Lancet. Gastroenterology & hepatology (2021)
Food antigen sensitization in genetically-susceptible mice is influenced by fecal IgA, antigen absorption, and gut microbiome composition
Authors: Johanna Smeekens, Brandi Johnson-Weaver, Andrew Hinton, M. Andrea Azcarate-Peril, Timothy Moran, Robert Immormino, Janelle Kesselring, Erin Steinbach, Kelly Orgel, Herman Staats, A. Wesley Burks, Peter Mucha, Martin Ferris, Mike Kulis
Journal: Journal of Allergy and Clinical Immunology (2021)